NCT03882034View on ClinicalTrials.gov

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Pituitary Disease
Interventions
DRUG

Pegvisomant

A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT03882034 - Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess | Biotech Hunter | Biotech Hunter